CERC - Cerecor Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
4.7550
-0.1950 (-3.94%)
As of 10:25AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close4.9500
Open4.5600
Bid4.63 x 800
Ask4.88 x 1000
Day's Range4.5600 - 4.8800
52 Week Range2.6380 - 5.7390
Volume6,502
Avg. Volume81,558
Market Cap194.024M
Beta (3Y Monthly)1.16
PE Ratio (TTM)N/A
EPS (TTM)-1.31
Earnings DateApr 1, 2019 - Apr 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.00
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    FDA Grants Cerecor’s Three Substrate Replacement Therapies Orphan Drug Designation

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of therapies for rare and orphan diseases in pediatrics and neurology, announced today that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designations (ODD) to Cerecor’s three substrate replacement therapies for Congenital Disorders of Glycosylation (CDGs). Each indication is an ultra-rare CDG estimated to have fewer than 1,000 patients in the United States.

  • GlobeNewswirelast month

    Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors

    Antares Pharma, Inc. (ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors.  Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of Cerecor Inc. (CERC), a biopharmaceutical company focused on neurological and pediatric disorders.  He is also Chairman of the Board at BioDelivery Sciences (BDSI), a specialty pharmaceutical company focused on pain management and addiction medicine.

  • Zacks Small Cap Research2 months ago

    CERC: Unveils Rare Pediatric Disease Programs…

    On October 31, 2018, Cerecor, Inc. (CERC) announced the submission of three Orphan Drug Designation (ODD) requests for three of the development products acquired from the purchase of Ichorion Therapeutics, Inc. Each of them is being developed for the treatment of ultrarare metabolic disorders known as Inborn Errors of Metabolism (IEM). CERC-801 (D-galactose): This is being developed for the treatment of Phosphoglucomutase 1 (PGM1) deficiency, a recently characterized congenital disorder of glycosylation (CDG). The multisystem deficiencies are a result of a lack of protein glycosylation, which is dependent upon the important metabolic intermediate glucose-1-phosphate.

  • What Kind Of Share Price Volatility Should You Expect For Cerecor Inc (NASDAQ:CERC)?
    Simply Wall St.2 months ago

    What Kind Of Share Price Volatility Should You Expect For Cerecor Inc (NASDAQ:CERC)?

    If you own shares in Cerecor Inc (NASDAQ:CERC) then it’s worth thinking about how it contributes to the volatility of your portfolio, overall. In finance, Beta is a measure of Read More...

  • GlobeNewswire2 months ago

    Analysis: Positioning to Benefit within KemPharm, Bellerophon Therapeutics, Exela Technologies, Intec Pharma, Cerecor, and Chiasma — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Cerecor Reports Third Quarter 2018 Results

    BALTIMORE, Nov. 13, 2018 -- Cerecor Inc. (“Cerecor” or the “Company”) (NASDAQ: CERC), a fully integrated biopharmaceutical company with commercial operations and research and.

  • GlobeNewswire3 months ago

    Cerecor Announces Submission of Three Orphan Drug Designation Requests for Substrate Replacement Therapies to treat Congenital Disorders of Glycosylation

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has submitted to the U.S. Food and Drug Administration (FDA) three Orphan Drug Designation (ODD) Requests for substrate replacement therapies to treat ultra-rare inherited metabolic disorders known as Congenital Disorders of Glycosylation (CDGs). Each indication is an ultra-rare CDG estimated to have less than 1,000 patients in the United States.

  • GlobeNewswire3 months ago

    Cerecor Receives Rare Pediatric Disease Designation for CERC-801 for Patients with Inborn Error of Metabolism

    Cerecor Inc. (CERC), a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases in pediatrics and neurology, announced today that it has been awarded Rare Pediatric Disease Designation (RPDD) from the U.S. Food and Drug Administration (FDA) for CERC-801. CERC-801 is a substrate replacement therapy to treat an ultra-rare inherited metabolic disorder known as an Inborn Error of Metabolism (IEM).

  • Zacks Small Cap Research4 months ago

    CERC: Transformation Continues with Purchase of Ichorion Therapeutics, Inc…

    Cerecor, Inc. (CERC) is a fully integrated pharmaceutical company with a diversified offering of commercial products and a development product portfolio. On September 25, 2018, Cerecor announced the acquisition of privately-held Ichorion Therapeutics, Inc., a biotechnology company focused on ultra-rare orphan diseases caused by inborn errors of metabolism (IEM). In addition, Ichorion has a platform to target IEMs that are not amenable to substrate replacement therapy.

  • Baltimore's Cerecor buys New York biotech for $26.6M in stock
    American City Business Journals4 months ago

    Baltimore's Cerecor buys New York biotech for $26.6M in stock

    The acquisition fits with Cerecor's recent transition to a greater focus on bringing pediatric therapeutics to market.

  • Investopedia5 months ago

    Penny Stocks to Buy Using Technical Analysis for September 2018

    Penny stocks approaching key price levels dominate September's technical analysis buy list, telling interested traders to build watch lists and track progress while awaiting fruitful buying signals or reversals that break bullish patterns. First, establish the price level that is likely to attract strong buying interest. Second, look for the price level that is likely to attract strong selling interest.

  • Zacks Small Cap Research5 months ago

    CERC: Phase 1 Trial of CERC-301 in nOH Underway

    Cerecor, Inc. (CERC) is a fully integrated pharmaceutical company with a diversified offering of commercial products and a development product portfolio. The company’s goal is to use cash flow from commercial operations to fund the development of the clinical product candidates. The company recorded net revenues of $4.8 million in the second quarter of 2018 compared to $0.2 million in the second quarter of 2017.

  • Investopedia6 months ago

    Penny Stocks to Watch for August 2018

    Penny stock pickers booked modest returns in these tough conditions, while trend followers and dart throwers took losses. The July penny stock list generated mixed returns, with precious metals and biotech headwinds limiting gains while a mid-month crude oil reversal undermined small energy plays.

  • May Top Undervalued Stock
    Simply Wall St.8 months ago

    May Top Undervalued Stock

    Undervalued companies are those that trade at a price lower than their actual values, such as Cerecor and China Yuchai International. There’s a few ways you can determine how muchRead More...

  • Zacks Small Cap Research8 months ago

    CERC: Converting into a Fully Independent Healthcare Company

    Following disappointing clinical trial results in 2016 and 2017, the company has pivoted to a new strategy through the acquisition of TRx Pharmaceuticals and the pediatric products from Avadel U.S. Holdings, Inc. While details of the company’s strategy are still coming together, in 2018 we believe investors should focus on the ability of management to continue growing the commercial side of the business, maintain business development activity, and advance the development pipeline. As the year progresses, we believe the company will provide additional details concerning all of those areas. The acquisition signifies Cerecor’s move to a pediatric-focused healthcare company and is being undertaken to provide a source of revenue to help fund the company’s development pipeline.